Hepatitis C virus-induced vasculitis: Therapeutic options

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 24-30

  Cacoub, Patrice ^a,b,c,d   Terrier, Benjamin ^e   Saadoun, David ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b Sorbonne Université   (France)

^c CNRS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ALPHA2B INTERFERON PLUS RIBAVIRIN; ANTIVIRUS AGENT; AZATHIOPRINE; BOCEPREVIR; CD4 ANTIGEN; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; FLUDARABINE; GLUCOCORTICOID; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN M; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; METHYLPREDNISOLONE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RITUXIMAB; TELAPREVIR; TRANSCRIPTION FACTOR FOXP3; UNINDEXED DRUG;

ANEMIA; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTHRALGIA; ASTHENIA; B CELL LYMPHOMA; BACTERIAL INFECTION; BIOLOGICAL THERAPY; BLOOD PROTEIN DISORDER; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); CRYOGLOBULINEMIA VASCULITIS; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; GLOMERULONEPHRITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; REVIEW; SALVAGE THERAPY; SKIN DISEASE; SKIN ULCER; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VASCULITIS;

INFECTIONS; SYSTEMIC VASCULITIS; TREATMENT;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; VASCULITIS;

EID: 84889683217     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203883     Document Type: Review

References (39)

1. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999;42:2204-12. (Pubitemid 30263607)
2. Trejo O, Ramos-Casals M, Garcia-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001;80:252-62. (Pubitemid 32703064)
3. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005;5:227-36. (Pubitemid 40410068)
4. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 2002;25:909-13. (Pubitemid 34579003)
5. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-6. (Pubitemid 24080221)
6. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907-17.
7. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994;84:3336-43. (Pubitemid 24352895)
8. Cacoub P, Lidove O, Maisonobe T, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002;46:3317-26. (Pubitemid 35453543)
9. Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000;27:2172-8.
10. Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005;42:632-8.
11. Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006;54:3696-706. (Pubitemid 44737183)
12. Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFNα/ribavirin/ protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis Published Online First: 20 April 2013. doi:10.1136/annrheumdis-2012-202770
13. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618-23.
14. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994;84:3336-43. (Pubitemid 24352895)
15. Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997;90:3865-73. (Pubitemid 27484038)
16. Hausfater P, Cacoub P, Assogba U, et al. Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron 2002;91:627-30. (Pubitemid 34914063)
17. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34. (Pubitemid 36857853)
18. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26. (Pubitemid 36857852)
19. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-61. (Pubitemid 40057628)
20. Cacoub P, Delluc A, Saadoun D, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67:283-7. (Pubitemid 351281259)
21. Sene D, Ghillani-Dalbin P, Amoura Z, et al. Rituximab may form a complex with IgM kappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009;60:3848-55.
22. Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011;11:48-55.
23. Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008;67:1431-6.
24. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:843-53.
25. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:835-42.
26. Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011;10:714-19.
27. Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010;116:335-42.
28. Terrier B, Saadoun D, Sene D, et al. Efficacy and tolerability of rituximab with or without pegylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009;60:2531-40.
29. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-{alpha}, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010;116:343-53.
30. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus peg-interferon-α/ ribavirin compared with peg-interferon-α/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-34.
31. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-77. 293
32. Landau DA, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008;58:604-11. (Pubitemid 351294898)
33. Saadoun D, De Chambrun MP, Hermine O, et al. Rituximab plus fludarabine and cyclophosphamide is an effective treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res (Hoboken) 2013;65(4):643-7. doi:10.1002/acr.21856
34. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980;69:287-308. (Pubitemid 10036826)
35. Meltzer M, Franklin EC, Elias K, et al. Cryoglobulinemia-a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966;40:837-56.
36. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74. (Pubitemid 38887136)
37. Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006;166:2101-8. (Pubitemid 44631398)
38. Terrier B, Semoun O, Saadoun D, et al. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum 2011;63:1748-57.
39. Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol 2013;25:10-18.